Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770939 | 0.78 | NPC1 (0.48) | POLBSIGMAR1MAPTLMNAMEN1 | |
| SCHEMBL6769586 | 0.73 | MEN1 (0.51) | POLBSIGMAR1MAPTLMNAMEN1 | |
| SCHEMBL4981821 | 0.73 | CYP2C9 (0.44) | ALDH1A1TSHRMAPT | |
| SCHEMBL6770940 | 0.73 | SIGMAR1 (0.60) | POLBSIGMAR1NOTUMALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL4984107 | 0.72 | CYP2C9 (0.42) | SIGMAR1ALDH1A1TSHRMAPTLMNA | |
| SCHEMBL6769984 | 0.69 | SIGMAR1 (0.55) | POLBSIGMAR1NOTUMALDH1A1TSHR | |
| SCHEMBL8335495 | 0.69 | HSD17B3 (0.45) | POLBTSHRMAPTLMNAMEN1 | |
| SCHEMBL4979723 | 0.68 | CYP2C9 (0.41) | ALDH1A1TSHRMAPTLMNA | |
| SCHEMBL6769101 | 0.67 | SIGMAR1 (0.52) | SIGMAR1NOTUMALDH1A1TSHRMAPT | |
| SCHEMBL4376794 | 0.65 | POLB (0.69) | POLBSIGMAR1NOTUMALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2003-08-14 | — | — | US | claimed |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2002-07-25 | — | — | US | claimed |
| US-6358993-B1 | TREATMENT OF NEUROLOGICAL INJURY AND NEURODEGENERATIVE DISORDERS; NEUROPROTECTIVE AGENTS; SUBSTITUTED INDOLINYL AND INDOLINYL GUANIDINE DERIVATIVES | CENES PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| EP-0925300-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-30 | — | — | EP | claimed |
| EP-0925300-A4 | — | — | 1999-06-30 | — | — | EP | claimed |
| WO-1997030054-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | POLB 3795/4885SIGMAR1 2813/4885NOTUM 439/4885 |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | POLB 3795/4885SIGMAR1 2813/4885NOTUM 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.